Gilead Sciences Inc (GILD)

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)

Market region: US

Address: 333 Lakeside Dr, Foster City, CA, 94404

Market capitalization

211.70 billion USD (211,700,994,638 USD)

Listing date

01/22/1992

Weighted shares outstanding

1,240,338,614

Share class shares outstanding

1,239,955,155

https://www.gilead.com